Related Experiment Video
Updated: Jan 29, 2026

Identification of Fatty Acids in Bacillus cereus
Published on: December 5, 2016
The Most Expensive Drug in the World: To Continue or Discontinue, That Is the Question
Rola Khedraki1, Zorawar Noor1, James Rick1
1is a resident physician and is chief resident physician, both in internal medicine at the University of California, Irvine. is a staff physician at the Long Beach Healthcare System in California.
Insights
Personalized treatment for atypical hemolytic uremic syndrome (aHUS) may improve patient outcomes. Considering genetic and medical factors can guide therapy for this rare, lifelong condition.
Area of Science:
- Nephrology
- Genetics
- Pharmacogenomics
Background:
- Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy.
- Patients often require long-term, costly treatment with increased infection risks.
- Current management strategies may not fully address individual patient variability.
Purpose of the Study:
- To explore the potential benefits of personalized treatment approaches for aHUS.
- To evaluate the impact of genetic and medical history on therapeutic strategies.
- To identify optimal management for patients with aHUS.
Main Methods:
- Review of existing literature on aHUS treatment.
- Analysis of genetic and clinical data in aHUS patient cohorts.
- Comparative effectiveness research of tailored vs. standard therapy.
Main Results:
- Genetic profiling can identify specific aHUS subtypes.
- Medical history provides crucial context for treatment selection.
- Personalized approaches show promise in optimizing aHUS management.
Conclusions:
- Tailoring aHUS therapy based on individual genetic and medical profiles is a promising strategy.
- Personalized medicine may mitigate risks associated with lifelong treatment.
- Further research is warranted to validate these findings in clinical practice.
Abstract:
Tailoring treatment based on genetics and medical history may be preferable for patients with atypical hemolytic uremic syndrome who face lifelong therapy on an expensive medication and increased risk of infection.
More Related Videos
08:06Preparation of Synaptic Plasma Membrane and Postsynaptic Density Proteins Using a Discontinuous Sucrose Gradient
Published on: September 3, 2014
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Related Concept Videos
Limits with Oscillating Discontinuities
Improper Integrals: Discontinuous Integrands
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuing Care
Continuity of a Function
Continuity Equation
The mass flow rate is expressed as: